ATE225405T1 - Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit - Google Patents

Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit

Info

Publication number
ATE225405T1
ATE225405T1 AT99401742T AT99401742T ATE225405T1 AT E225405 T1 ATE225405 T1 AT E225405T1 AT 99401742 T AT99401742 T AT 99401742T AT 99401742 T AT99401742 T AT 99401742T AT E225405 T1 ATE225405 T1 AT E225405T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
preventing
prognosis
diagnosis
Prior art date
Application number
AT99401742T
Other languages
English (en)
Inventor
Vincent Mooser
Nicole Helbecque
Philippe Amouyel
Original Assignee
Pasteur Institut
Chu Vaudois Lausanne
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Chu Vaudois Lausanne, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE225405T1 publication Critical patent/ATE225405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99401742T 1999-07-09 1999-07-09 Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit ATE225405T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99401742A EP1074634B1 (de) 1999-07-09 1999-07-09 Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit

Publications (1)

Publication Number Publication Date
ATE225405T1 true ATE225405T1 (de) 2002-10-15

Family

ID=8242047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99401742T ATE225405T1 (de) 1999-07-09 1999-07-09 Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit

Country Status (6)

Country Link
EP (1) EP1074634B1 (de)
JP (1) JP2003504606A (de)
AT (1) ATE225405T1 (de)
AU (1) AU6823600A (de)
DE (1) DE69903278D1 (de)
WO (1) WO2001004349A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
GB0200757D0 (en) * 2002-01-15 2002-02-27 Univ Manchester Diagnostic methods
KR20060018851A (ko) * 2003-05-16 2006-03-02 교와 핫꼬 고교 가부시끼가이샤 조직 파괴를 수반하는 질환의 예방 및/또는 치료제
JP4884367B2 (ja) 2004-02-24 2012-02-29 アボット・ヘルスケア・プロダクツ・ベスローテン・フェンノートシャップ 神経疾患を発症する危険性を決定するための方法
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
WO2007092380A2 (en) * 2006-02-06 2007-08-16 Berkeley Heartlab, Inc. Apolipoprotein e genotyping and accompanying internet-based health management system
AU2010264524B2 (en) 2009-06-22 2015-03-19 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
CN108346468B (zh) * 2017-12-27 2021-03-23 北京科迅生物技术有限公司 数据处理方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716894B1 (fr) * 1994-03-07 1996-05-24 Pasteur Institut Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
US5599706A (en) * 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)

Also Published As

Publication number Publication date
JP2003504606A (ja) 2003-02-04
WO2001004349A2 (en) 2001-01-18
AU6823600A (en) 2001-01-30
DE69903278D1 (de) 2002-11-07
WO2001004349A3 (en) 2001-05-25
EP1074634B1 (de) 2002-10-02
EP1074634A1 (de) 2001-02-07

Similar Documents

Publication Publication Date Title
DE69729654D1 (de) Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit
WO2003016494A3 (en) Diagnosis and treatment of vascular disease
DE625212T1 (de) Verfahren zum entdecken von krankheit von alzheimer.
FI964284A0 (fi) Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
Rozycka et al. Evidence for S284L mutation of the CHRNA4 in a white family with autosomal dominant nocturnal frontal lobe epilepsy
ATE225405T1 (de) Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit
DE60016242D1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
ATE317452T1 (de) Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
ATE169343T1 (de) Gemeinschaftlich verwendete genetische marker zur diagnostik der alzheimerschen krankheit, methode und diagnostischer reagenziensatz
DE60231222D1 (de) Herz-kreislauf-erkrankung vorhersagende einzelnukleotid-polymorphismen
MXPA02000293A (es) Isoformas de la amp ciclico fosfodiesterasa y metodos de uso.
ATE283703T1 (de) Neurodegenerative-erkrankung verwandtes gen
WO2003020120A3 (en) Diagnosis and treatment of vascular disease
Klopstock et al. Markedly different course of Friedreich’s ataxia in sib pairs with similar GAA repeat expansions in the frataxin gene
WO2003020911A3 (en) Human schizophrenia gene
Boschann et al. Biallelic variants in ADAMTS15 cause a novel form of distal arthrogryposis
DE60031518D1 (de) Methode zur Diagnostizierung, Prognose oder Evaluation von Behandlung der Depressionen, basiert auf erhöhte Neurotrophin Concentrationen in zerebrospinale Flüssigkeit.
DE69834831D1 (de) Gen, das im zusammenhang steht mit gemütskrankheiten
DE60212861D1 (de) Verfahren zur Diagnose von Fettsucht
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps
ATE365175T1 (de) Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties